Environmental toxins and Parkinson's disease: Putative roles of impaired electron transport chain and oxidative stress

Toxicology and Industrial Health

Volumn 26, Issue 2, 2010, Pages 121-128

  Abdulwahid Arif, Ibrahim ^a   Ahmad Khan, Haseeb ^a  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

electron transport chain; environmental toxins; mitochondrial respiration; neurodegeneration; oxidative stress; Parkinson's disease

Indexed keywords

BREATHING; CHEMICALLY INDUCED DISORDER; DANGEROUS GOODS; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ELECTRON TRANSPORT; HUMAN; INTOXICATION; METABOLISM; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; DOPAMINERGIC TRANSMISSION; ENVIRONMENTAL EXPOSURE; MITOCHONDRIAL RESPIRATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; RESPIRATORY CHAIN;

ELECTRON TRANSPORT; HAZARDOUS SUBSTANCES; HUMANS; MITOCHONDRIAL DISEASES; MPTP POISONING; OXIDATIVE STRESS; PARKINSON DISEASE; RESPIRATION;

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOSINE TRIPHOSPHATE; PARAQUAT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE DEHYDROGENASE; ROTENONE; UBIDECARENONE;

ANIMALIA;

EID: 77951909047     PISSN: 07482337     EISSN: None     Source Type: Journal    
DOI: 10.1177/0748233710362382     Document Type: Article

References (69)

1. Antunes F., Han D., Rettori D., and Cadenas E. (2002) Mitochondrial damage by nitric oxide is potentiated by dopamine in PC12 cells. Biochimica et Biophysica Acta 1556: 233-238.
2. Ballard PA, Tetrud JW, and Langston JW (1985) Permanent human Parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 35: 949-956.
3. Berman SB, Hastings TG (1999) Dopamine oxidation alters mitochondrial respiration and induces permeability transition in brain mitochondria: implications for Parkinson’s disease. Journal of Neurochemistry 73: 1127-1137.
4. Betarbet R., Sherer TB, MacKenzie G., Garcia-Osuna M., Panov AV, and Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nature Neuroscience 3: 1301-1306.
5. Castello PR, Drechsel DA, and Patel M. (2007) Mitochondria are a major source of paraquat-induced reactive oxygen species production in the brain. Journal of Biological Chemistry 282: 14186-14193.
6. Chen Q., Vazquez EJ, Moghaddas S., et al. (2003) Production of reactive oxygen species by mitochondria. Journal of Biological Chemistry 278: 36027-36031.
7. Chiba K., Trevor AJ, and Castagnoli N. Jr (1984) Metabolism of the neurotoxin tertiary amine MPTP, by brain monoamine oxidase. Biochemical and Biophysical Research Communications 120: 574-578.
8. Chinopoulos C., Adam-Vizi V. (2001) Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson’s disease. Journal of Neurochemistry 76: 302-306.
9. Choi HJ, Lee SY, Cho Y., No H., Kim SW, and Hwang O. (2006) Tetrahydrobiopterin causes mitochondrial dysfunction in dopaminergic cells: implications for Parkinson’s disease. Neurochemistry International 48: 255-262.
10. Choi WS, Kruse SE, Palmiter RD, and Xia Z. (2008) Mitochondrial complex I inhibition is not required for dopaminergic neuron death induced by rotenone, MPP+, or paraquat. Proceedings of National Academy of Science USA 105: 15136-15141.
11. Cochemé HM, Murphy MP (2008) Complex I is the major site of mitochondrial superoxide production by paraquat. Journal of Biological Chemistry 283: 1786-1798.
12. Cormier A., Morin C., Zini R., Tillement JP, and Lagrue G. (2003) Nicotine protects rat brain mitochondria against experimental injuries. Neuropharmacology 44: 642-652.
13. Costello S., Cockburn M., Bronstein J., Zhang X., and Ritz B. (2009) Parkinson’s disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. American Journal of Epidemiology 169: 919-926.
14. Dauer W., Kholodilov N., Vila M., et al. (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proceedings of National Academy of Science USA 99: 14524-14529.
15. Desai VG, Feuers RJ, Hart RW, and Ali SF (1996) MPP(+)-induced neurotoxicity in mouse is age-dependent: evidenced by the selective inhibition of complexes of electron transport. Brain Research 715: 1-8.
16. Dhillon AS, Tarbutton GL, Levin JL, Plotkin GM, Lowry LK, and Nalbone JT (2008) Pesticide/environmental exposures and Parkinson’s disease in East Texas. Journal of Agromedicine 13: 37-48.
17. Dinis-Oliveira RJ, Remião F., Carmo H., Duarte JA, Navarro AS, Bastos ML, et al. (2006) Paraquat exposure as an etiological factor of Parkinson’s disease. Neurotoxicology 27: 1110-1122.
18. Drechsel DA, Patel M. Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parkinson’s disease (2008) Free Radical Biology and Medicine 44: 1873-1886.
19. Fei Q., McCormack AL, Di Monte DA, and Ethell DW (2008) Paraquat neurotoxicity is mediated by a Bakdependent mechanism. Journal of Biological Chemistry 283: 3357-3364.
20. Fiskum G., Starkov A., Polster BM, and Chinopoulos C. (2003) Mitochondrial mechanisms of neural cell death and neuroprotective interventions in Parkinson’s disease. Annals of the New York Academy of Sciences 991: 111-119.
21. Fukushima T., Tawara T., Isobe A., Hojo N., Shiwaku K., and Yamane Y. (1995) Radical formation site of cerebral complex I and Parkinson’s disease. Journal of Neuroscience 42: 385-390.
22. Fukushima T., Yamada K., Hojo N., Isobe A., Shiwaku K., and Yamane Y. (1994) Mechanism of cytotoxicity of paraquat. III. The effects of acute paraquat exposure on the electron transport system in rat mitochondria. Experimental & Toxicologic Pathology 46: 437-441.
23. Gluck MR, Zeevalk GD (2004) Inhibition of brain mitochondrial respiration by dopamine and its metabolites: implications for Parkinson’s disease and catecholamine-associated diseases. Journal of Neurochemistry 91: 788-795.
24. Gomez C., Bandez MJ, and Navarro A. (2007) Pesticides and impairment of mitochondrial function in relation with the parkinsonian syndrome. Frontiers in Bioscience 12: 1079-1093.
25. Gorell JM, Johnson CC, Rybicki BA, Peterson EL, and Richardson RJ (1998) The risk of Parkinson’s disease with exposure to pesticides, farming, well water, and rural living. Neurology 50: 1346-1350.
26. Gorman AM, Ceccatelli S., and Orrenius S. (2000) Role of mitochondria in neuronal apoptosis. Developmental Neuroscience 22: 348-358.
27. Greenamyre JT, Sherer TB, Betarbet R., and Panov AV (2001) Complex I and Parkinson’s disease. International Union of Biochemistry and Molecular Biology Life 52: 135-141.
28. Hattori N., Ikebe S., Tanaka M., et al. (1993) Immunohistochemical studies on complexes I, II, III and IV of mitochondria in Parkinson’s disease. Advances in Neurology 60: 292-296.
29. Hsu LJ, Sagara Y., Arroyo A., et al. (2000) Alpha-synuclein promotes mitochondrial deficit and oxidative stress. American Journal of Pathology 157: 401-410.
30. Imamura K., Takeshima T., Kashiwaya Y., Nakaso K., and Nakashima K. (2006) D-beta-hydroxybutyrate protects dopaminergic SH-SY5Y cells in a rotenone model of Parkinson’s disease. Journal of Neuroscience Research 84: 1376-1384.
31. Itoh K., Weis S., Mehraein P., et al. (1997) Defects of cytochrome c oxidase in the substantia nigra of Parkinson’s disease: and immunohistochemical and morphometric study. Movement Disorders 12: 9-16.
32. Janetzky B., Hauck S., Youdim MB, et al. (1994) Unaltered aconitase activity but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson’s disease. Neuroscience Letters 169: 126-128.
33. Keeney PM, Xie J., Capaldi RA, and Bennett JP Jr (2006) Parkinson’s disease brain mitochondrial complex I has oxidatively damaged subunits and is functionally impaired and misassembled. Journal of Neuroscience 26: 5256-5264.
34. Langston JW, Fomo LS, Rebert CS, and Irwin I. (1984) Selective nigral toxicity after systemic administration of I-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Research 292: 390-394.
35. Lannuzel A., Michel PP, Höglinger GU, et al. (2003) The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism. Neuroscience 121: 287-296.
36. Liang CL, Wang TT, Luby-Phelps K., and German DC (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson’s disease. Experimental Neurology 203: 370-380.
37. Liu Y., Fiskum G., and Schubert D. (2002) Generation of reactive oxygen species by the mitochondrial electron transport chain. Journal of Neurochemistry 80: 780-787.
38. Menegon A, Board PG, Blackburn AC, Mellick GD, and Le Couteur DG. (1998) Parkinson’s disease, pesticides, and glutathione transferase polymorphisms. Lancet 352: 1344-1346.
39. Mortiboys HJ, Schaefer J., Reichmann H., and Jackson S. (2007) Mitochondrial dysfunction in Parkinson’s disease-revisited. Neurologia i Neurochirurgia Polska 41: 150-159.
40. Müftüoglu M., Elibol B., Dalmizrak O., et al. (2003) Mitochondrial complex I and IV activities in leukocytes from patients with parkin mutations. Movement Disorder 19: 544-580.
41. Nicklas WJ, Vyas I., and Heikkila RE (1985) Inhibition of NADH linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Life Sciences 36:2503-2508.
42. Nunes C., Almeida L., and Laranjinha J. (2005) Synergistic inhibition of respiration in brain mitochondria by nitric oxide and dihydroxyphenylacetic acid (DOPAC). Implications for Parkinson’s disease. Neurochemical International 47: 173-182.
43. Orth M., Tabrizi SJ, Schapira AH, et al. (2003) Alpha-synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. Neuroscience Letters 351: 29-32.
44. Palacino JJ, Sagi D., Goldberg MS, Krauss S., Motz C., Wacker M., et al. (2004) Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. Journal of Biological Chemistry 279: 18614-18622.
45. Palmeira CM, Moreno AJ, and Madeira VM (1995) Mitochondrial bioenergetics is affected by the herbicide paraquat. Biochimica et Biophysica Acta 1229: 187-192.
46. Panov A., Dikalov S., Shalbuyeva N., Taylor G., Sherer T., and Greenamyre JT (2005) Rotenone model of Parkinson disease: multiple brain mitochondria dysfunctions after short term systemic rotenone intoxication. Journal of Biological Chemistry 280: 42026-42035.
47. Parker WD Jr, Parks JK, and Swerdlow RH (2008) Complex I deficiency in Parkinson’s disease frontal cortex. Brain Research 1189: 215-218.
48. Patel S., Sinha A., and Singh MP (2007) Identification of differentially expressed proteins in striatum of maneb-and paraquat-induced Parkinson’s disease phenotype in mouse. Neurotoxicology Teratology 29: 578-585.
49. Peng J., Peng L., Stevenson FF, Doctrow SR, and Andersen JK (2007) Iron and paraquat as synergistic environmental risk factors in sporadic Parkinson’s disease accelerate age-related neurodegeneration. Journal of Neuroscience 27: 6914-6922.
50. Prasad K., Winnik B., Thiruchelvam MJ, Buckley B., Mirochnitchenko O., and Richfield EK (2007) Prolonged toxicokinetics and toxicodynamics of paraquat in mouse brain. Environmental Health Perspective 115: 1448-1453.
51. Przedborski S., Jackson-Lewis V. (1998) Mechanisms of MPTP toxicity. Movement Disorder 13: 35-38.
52. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., et al. (2000) The parkinsonian toxin MPTP: action and mechanism. Restorative Neurology and Neurosciences 16: 135-142.
53. Ramsay RR, Kowal AT, Johnson MK, Salach JI, and Singer TP (1987) The inhibition site of MPP+, the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine is near the Q-binding site of NADH dehydrogenase. Archives of Biochemistry and Biophysics 259: 645-649.
54. Richardson JR, Quan Y., Sherer TB, Greenamyre JT, and Miller GW (2005) Paraquat neurotoxicity is distinct from that of MPTP and rotenone. Toxicological Science 88: 193-201.
55. Rojo AI, Cavada C., de Sagarra MR, and Cuadrado A. (2007) Chronic inhalation of rotenone or paraquat does not induce Parkinson’s disease symptoms in mice or rats. Experimental Neurology 208: 120-126.
56. Schapira AH, Cooper JM, Dexter D., et al. (1990) Mitochondrial complex I deficiency in Parkinson’s disease. Journal of Neurochemistry 54:823-827.
57. Seaton TA, Cooper JM, and Schapira AH (1997) Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors. Brain Research 777: 110-118.
58. Seo BB, Nakamaru-Ogiso E., Flotte TR, Matsuno-Yagi A., and Yagi T. (2006) In vivo complementation of complex I by the yeast Ndi1 enzyme. Possible application for treatment of Parkinson disease. Journal of Biological Chemistry 281: 14250-14255.
59. Sharma SK, El Refaey H., and Ebadi M. (2006) Complex-1 activity and 18F-DOPA uptake in genetically engineered mouse model of Parkinson’s disease and the neuroprotective role of coenzyme Q10. Brain Research Bulletin 70: 22-32.
60. Sherer TB, Betarbet R., Stout AK, Lund S., Baptista M., Panov AV, et al. (2002) An in vitro model of Parkinson’s disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage. Journal of Neurosciences 22: 7006-7015.
61. Song DD, Shults CW, Sisk A., et al. (2004) Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Experimental Neurology 186: 158-172.
62. Storch A. (2007) Coenzyme Q10 in Parkinson’s disease. Symptomatic or neuroprotective effects? Nervenarzt 78: 1378-1382.
63. Storch A., Jost WH, Vieregge P., et al. (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Archives of Neurology 64: 938-944.
64. Takeshige K. Superoxide formation and lipid peroxidation by the mitochondrial electron-transfer chain. Rinsho Shinkeigaku 34: 1269-1271.
65. Tawara T., Fukushima T., Hojo N., Isobe A., Shiwaku K., Setogawa T., et al. (1996) Effects of paraquat on mitochondrial electron transport system and catecholamine contents in rat brain. Archives of Toxicology 70: 585-589.
66. Tieu K., Perier C., Caspersen C., et al. (2003) D-beta-hydroxybutyrate rescues mitochondrial respiration and mitigates features of Parkinson disease. Journal of Clinical Investigation 112: 892-901.
67. Winkler-Stuck K., Kirches E., Mawrin C., Dietzmann K., Lins H., Wallesch CW, et al. (2005) Re-evaluation of the dysfunction of mitochondrial respiratory chain in skeletal muscle of patients with Parkinson’s disease. Journal of Neural Transmission 112: 499-518.
68. Yang W., Tiffany-Castiglioni E. (2005) The bipyridyl herbicide paraquat produces oxidative stress-mediated toxicity in human neuroblastoma SH-SY5Y cells: relevance to the dopaminergic pathogenesis. Journal of Toxicology and Environmental Health A 68: 1939-1961.
69. Zhang W., Wang T., Qin L., Gao HM, Wilson B., Ali SF, et al. (2004) Neuroprotective effect of dextromethorphan in the MPTP Parkinson’s disease model: role of NADPH oxidase. FASEB Journal 18: 589-591.